The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Atyr Pharma Inc. Common Stock 002120103 637 130,572 SH   SOLE   130,572 0 0
Dare Bioscience, Inc. Common Stock 23666P101 617 326,240 SH   SOLE   326,240 0 0
Fate Therapeutics, Inc. Common Stock 31189P102 49,461 569,889 SH   SOLE   569,889 0 0
Genocea Biosciences, Inc. Common Stock 372427401 462 197,345 SH   SOLE   197,345 0 0
Lyra Therapeutics, Inc. Common Stock 55234L105 8,840 1,100,852 SH   SOLE   1,100,852 0 0
Pulmatrix, Inc. Common Stock 74584P202 374 359,441 SH   SOLE   359,441 0 0
x4 Pharmaceuticals Inc. Common Stock 98420x103 2,025 311,492 SH   SOLE   311,492 0 0